Emamuzo Otobo

Emamuzo Otobo

Auto-generated profile, based on publicly available information

Emamuzo Otobo

Icahn School of Medicine at Mount Sinai, New York, NY, United States

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2015 in JMIR Research Protocols
Verified
Journal Article
Open access
AAAshish Atreja
Ashish Atreja
SKSameer Khan
Sameer Khan
JRJason D Rogers
Jason D Rogers
EOEmamuzo Otobo
Emamuzo Otobo
NPNishant P Patel
Nishant P Patel
HGHealthPROMISE Consortium Group
HealthPROMISE Consortium Group
Inflammatory bowel disease (IBD) is a chronic condition of the bowel that affects over 1 million people in the United States. The recurring nature of disease makes IBD patients ideal candidates for patient-engaged care that is centered on enhanced self-management and improved doctor-patient communication. In IBD, optimal approaches to management vary for patients with different phenotypes and extent of disease and past surgical history. Hence, a single quality metric cannot define a heterogeneous disease such as IBD, unlike hypertension and diabetes. A more comprehensive assessment may be provided by complementing traditional quality metrics with measures of the patient's quality of life (QOL) through an application like HealthPROMISE. The objective of this pragmatic randomized controlled trial is to determine the impact of the HealthPROMISE app in improving outcomes (quality of care [QOC], QOL, patient adherence, disease control, and resource utilization) as compared to a patient education app. Our hypothesis is that a patient-centric self-monitoring and collaborative decision support platform will lead to sustainable improvement in overall QOL for IBD patients. Participants will be recruited during face-to-face visits and randomized to either an interventional (ie, HealthPROMISE) or control (ie, education app). Patients in the HealthPROMISE arm will be able to update their information and receive disease summary, quality metrics, and a graph showing the trend of QOL (SIBDQ) scores and resource utilization over time. Providers will use the data for collaborative decision making and quality improvement interventions at the point of care. Patients in the control arm will enter data at baseline, during office visits, and at the end of the study but will not receive any decision support (trend of QOL, alert, or dashboard views). Enrollment in the trial will be starting in first quarter of 2015. It is intended that up to 300 patients with IBD will be recruited into the study (with 1:1 allocation ratio). The primary endpoint is number of quality indicators met in HealthPROMISE versus control arm. Secondary endpoints include decrease in number of emergency visits due to IBD, decrease in number of hospitalization due to IBD, change in generic QOL score from baseline, proportion of patients in each group who meet all eligible outpatient quality metrics, and proportion of patients in disease control in each group. In addition, we plan to conduct protocol analysis of intervention patients with adequate HealthPROMISE utilization (more than 6 log-ins with data entry from week 0 through week 52) achieving above mentioned primary and secondary endpoints. HealthPROMISE is a unique cloud-based patient-reported outcome (PRO) and decision support tool that empowers both patients and providers. Patients track their QOL and symptoms, and providers can use the visual data in real time (integrated with electronic health records [EHRs]) to provide better care to their entire patient population. Using pragmatic trial design, we hope to show that IBD patients who participate in their own care and share in decision making have appreciably improved outcomes when compared to patients who do not. ClinicalTrials.gov NCT02322307; https://clinicaltrials.gov/ct2/show/NCT02322307 (Archived by WebCite at http://www.webcitation.org/6W8PoYThr).

15 November 2019 in JMIR Medical Informatics
Verified
Journal Article
Open access
CPChristopher Park
Christopher Park
EOEmamuzo Otobo
Emamuzo Otobo
JUJennifer Ullman
Jennifer Ullman
JRJason Rogers
Jason Rogers
FFFarah Fasihuddin
Farah Fasihuddin
AAAshish Atreja
Ashish Atreja
Background: Heart failure (HF) is a condition that affects approximately 6.2 million people in the United States and has a 5-year mortality rate of approximately 42%. With the prevalence expected to exceed 8 million cases by 2030, projections estimate that total annual HF costs will increase to nearly US $70 billion. Recently, the advent of remote monitoring technology has significantly broadened the scope of the physician’s reach in chronic disease management. Objective: The goal of our program, named the Heart Health Program, was to examine the feasibility of using digital health monitoring in real-world home settings, ascertain patient adoption, and evaluate impact on 30-day readmission rate. Methods: A digital medicine software platform developed at Mount Sinai Health System, called RxUniverse, was used to prescribe a digital care pathway including the HealthPROMISE digital therapeutic and iHealth mobile apps to patients’ personal smartphones. Vital sign data, including blood pressure (BP) and weight, were collected through an ambulatory remote monitoring system that comprised a mobile app and complementary consumer-grade Bluetooth-connected smart devices (BP cuff and digital scale) that send data to the provider care teams. Care teams were alerted via a Web-based dashboard of abnormal patient BP and weight change readings, and further action was taken at the clinicians’ discretion. We used statistical analyses to determine risk factors associated with 30-day all-cause readmission. Results: Overall, the Heart Health Program included 58 patients admitted to the Mount Sinai Hospital for HF. The 30-day hospital readmission rate was 10% (6/58), compared with the national readmission rates of approximately 25% and the Mount Sinai Hospital’s average of approximately 23%. Single marital status (P=.06) and history of percutaneous coronary intervention (P=.08) were associated with readmission. Readmitted patients were also less likely to have been previously prescribed angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (P=.02). Notably, readmitted patients utilized the BP and weight monitors less than nonreadmitted patients, and patients aged younger than 70 years used the monitors more frequently on average than those aged over 70 years, though these trends did not reach statistical significance. The percentage of the 58 patients using the monitors at least once dropped from 83% (42/58) in the first week after discharge to 46% (23/58) in the fourth week. Conclusions: Given the increasing burden of HF, there is a need for an effective and sustainable remote monitoring system for HF patients following hospital discharge. We identified clinical and social factors as well as remote monitoring usage trends that identify targetable patient populations that could benefit most from integration of daily remote monitoring. In addition, we demonstrated that interventions driven by real-time vital sign data may greatly aid in reducing hospital readmissions and costs while improving patient outcomes.

18 January 2018 in Inflammatory Bowel Diseases
Verified
Journal Article
Open access
PDF file
AAAshish Atreja
Ashish Atreja
EOEmamuzo Otobo
Emamuzo Otobo
ESEva Szigethy
Eva Szigethy
AKAkshay Kohli
Akshay Kohli
HSHersh Shroff
Hersh Shroff
BSBruce E. Sands
Bruce E. Sands
The recurrent and debilitating nature of Inflammatory Bowel Disease (IBD) makes affected patients ideal candidates to assess the therapeutic potential of a digital intervention for long-term patient management. HealthPROMISE is an innovative software platform designed to improve health outcomes by increasing patient engagement, self-management skills and communication transparency. The study aims to understand the impact of the use of a mobile based remote app on improving quality of care (QOC), health outcomes and quality of life (QOL) in IBD patients. Demographic information and baseline e-PROs (Patient-Reported Outcomes) were measured using online questionnaires delivered through the mobile based monitoring app. In the app, patients update their information and receive a disease summary of QOC metrics and IBD-specific QOL trends. Patient data was monitored in real-time and communicated with the care team and patients as needed. •320 patients were enrolled and randomized to intervention (162) and control (158) group (Fig.1) •IBD-QOL significantly improved among HealthPROMISE patients over a follow-up of 575 days (25.2 ± 11.3 vs. 30.3 ± 11.3 baseline, p<0.001). •Uncontrolled anxiety and fatigue were major drivers of poor QOL. •Patients with a college education reported significantly less symptom burden (29.3vs 36.8, range 10–70; P<0.001). •After a follow-up of 575 ± 135 days, more significant increase in QOC was observed among HealthPROMISE users (+34 ppt vs. +15 ppt, p<0.01) (Fig.2). A significant improvement in QOC was observed among patients using the mobile based app, who also reported more equitable participation in their care decision-making process and improved health outcomes. Digital health interventions and IBD remote monitoring can address gaps in QOC, increase patient engagement, improve QOL and health outcomes. This is one of the first randomized controlled trials of app-based PRO in IBD patients. Study inclusion/exclusion criteria flowchart. Study inclusion/exclusion criteria flowchart. Change in percentage of patients meeting eligible qoc metrics at 495 days from baseline (+9 pp control vs. +28 Pp healthpromise, p<0.01) And at 575 days from baseline (+15 ppt control vs. +34 Ppt healthpromise, p<0.01). Change in percentage of patients meeting eligible qoc metrics at 495 days from baseline (+9 pp control vs. +28 Pp healthpromise, p<0.01) And at 575 days from baseline (+15 ppt control vs. +34 Ppt healthpromise, p<0.01).

31 January 2019 in JMIR Preprints
Verified
Preprint
Open access
CPChristopher Park
Christopher Park
EOEmamuzo Otobo
Emamuzo Otobo
JUJennifer Ullman
Jennifer Ullman
JRJason Rogers
Jason Rogers
FFFarah Fasihuddin
Farah Fasihuddin
AAAshish Atreja
Ashish Atreja
BACKGROUND Heart failure (HF) is a condition that affects approximately 6.2 million people in the United States and has a 5-year mortality rate of approximately 42%. With the prevalence expected to exceed 8 million cases by 2030, projections estimate that total annual HF costs will increase to nearly US $70 billion. Recently, the advent of remote monitoring technology has significantly broadened the scope of the physician’s reach in chronic disease management. OBJECTIVE The goal of our program, named the Heart Health Program, was to examine the feasibility of using digital health monitoring in real-world home settings, ascertain patient adoption, and evaluate impact on 30-day readmission rate. METHODS A digital medicine software platform developed at Mount Sinai Health System, called RxUniverse, was used to prescribe a digital care pathway including the HealthPROMISE digital therapeutic and iHealth mobile apps to patients’ personal smartphones. Vital sign data, including blood pressure (BP) and weight, were collected through an ambulatory remote monitoring system that comprised a mobile app and complementary consumer-grade Bluetooth-connected smart devices (BP cuff and digital scale) that send data to the provider care teams. Care teams were alerted via a Web-based dashboard of abnormal patient BP and weight change readings, and further action was taken at the clinicians’ discretion. We used statistical analyses to determine risk factors associated with 30-day all-cause readmission. RESULTS Overall, the Heart Health Program included 58 patients admitted to the Mount Sinai Hospital for HF. The 30-day hospital readmission rate was 10% (6/58), compared with the national readmission rates of approximately 25% and the Mount Sinai Hospital’s average of approximately 23%. Single marital status (P=.06) and history of percutaneous coronary intervention (P=.08) were associated with readmission. Readmitted patients were also less likely to have been previously prescribed angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers (P=.02). Notably, readmitted patients utilized the BP and weight monitors less than nonreadmitted patients, and patients aged younger than 70 years used the monitors more frequently on average than those aged over 70 years, though these trends did not reach statistical significance. The percentage of the 58 patients using the monitors at least once dropped from 83% (42/58) in the first week after discharge to 46% (23/58) in the fourth week. CONCLUSIONS Given the increasing burden of HF, there is a need for an effective and sustainable remote monitoring system for HF patients following hospital discharge. We identified clinical and social factors as well as remote monitoring usage trends that identify targetable patient populations that could benefit most from integration of daily remote monitoring. In addition, we demonstrated that interventions driven by real-time vital sign data may greatly aid in reducing hospital readmissions and costs while improving patient outcomes.